Key facts
- It has raised $13.5M across 2 recorded rounds; the latest was Accelerator/Incubator in Mar 2025.
- Notable investors include Springboard Enterprises, Flybridge (New York), XFactor Ventures, Sacramento Angels, Bonaventure Equity — 10 tracked in total.
- Nalu Bio has filed 1 Form D with the SEC, most recently Mar 2023 ($4.8M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Nalu Bio
Funding rounds
2 roundsAbout Nalu Bio
Developer of a drug discovery tool designed to accelerate the development of prescription and nonprescription health products targeting the endocannabinoid system (ECS). The company's platform combines generative artificial intelligence with emerging science to design, model, and screen novel compounds, enabling the health and wellness market to address critical issues such as pain, weight management, stress, and sleep disorders with minimal side effects on a global scale.
- Industry
- Other Pharmaceuticals and Biotechnology
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2019
- Employees
- 19
- Website
- nalubio.com/
- Ownership
- Privately Held (backing)
Nalu Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nalu Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nalu Bio in its N-PORT filings yet. We sweep new filings monthly.